✨ Free AI Report
Insitro, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Insitro, Inc.
Company Research

Insitro, Inc.: Business Overview, Financials & Competitive Analysis

Insitro, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Leading AI-native drug discovery platform with significant pharma partnerships, demonstrated technology convergence, and focused pipeline in high-value metabolic and neuroscience markets. Insitro has raised approximately $800M in capital, including approximately $150M from non-dilutive pharma partnerships, demonstrating strong market validation and strategic pharma alignment. As of May 31, 2026, the latest.

What is Insitro, Inc.'s industry? Insitro, Inc. (insitro.com) operates in Drug Discovery Services. AskCyborg classifies Insitro, Inc. under Drug Discovery Services in its company registry.

Insitro is an AI therapeutics company built on causal biology that generates an integrated, multimodal corpus of human and cellular data and analyzes it with machine learning to reveal how disease begins, progresses, ...

8/ 10Strong

Cyborg Score thesis

Leading AI-native drug discovery platform with significant pharma partnerships, demonstrated technology convergence, and focused...

Read the full analyst-debate transcript →
Industry Drug Discovery Services
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Insitro, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Insitro, Inc.

AskCyborg analysts argue the bull and bear cases for Insitro, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Insitro, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Insitro, Inc. Overview

Pro stress-test →

Insitro is an AI therapeutics company built on causal biology that generates an integrated, multimodal corpus of human and cellular data and analyzes it with machine learning to reveal how disease begins, progresses, and can be resolved. The company is building a different kind of drug company to bring better drugs faster to patients who can benefit most through the power of machine learning and data at scale to decode the complexities of biology.

Strategic Profile

Pro stress-test →

Insitro completed its full stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics with an integrated approach that accelerates the generation of clinic-ready assets while reducing late-stage development risk. The company applies its approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience.

Competitive Landscape

Pro stress-test →

Exscientia, Numerion Labs, Verge Genomics, and Recursion Pharmaceuticals are competitors of Insitro. Insitro differentiates through its causal biology approach, full-stack platform spanning multiple modalities, and strategic pharma partnerships. Insitro stands 1st in terms of total funding among its competitors.

Industry Context

Insitro, Inc. operates in Drug Discovery Services.

Key facts

Founded: 2018 · Headquarters: South San Francisco, US · Employees: 254 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Insitro, Inc..

  • In January 2026, Insitro acquired CombinAbleAI and launched its TherML platform, completing full-stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and complex biologics.
  • Insitro received $25 million in milestone payments from Bristol Myers Squibb for the achievement of discovery milestones and the selection of first novel genetic target for ALS.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Bristol-Myers Squibb collaboration expanded with nomination of new targets for genetic programs
  • February 2026Completed first AI-enabled human genetics study of brown adipose tissue with differentiated anti-obesity targets
  • +2 moreTrack every material event for Insitro, Inc. as it happens. Explore monitoring →
Get alerted when Insitro, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ExscientiaAI-driven drug discovery platform→Recursion PharmaceuticalsMachine learning-enabled drug discovery→Verge GenomicsAI-powered genetic target discovery→Numerion LabsComputational drug discovery→

Compare Insitro, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Insitro, Inc. operates in Drug Discovery Services. See how the rest of the sector scores on the Cyborg framework.

Browse Drug Discovery Services research →
NEW · MCP server

Ask your AI assistant about Insitro, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Insitro, Inc. and its top competitor on Cyborg Score”
“What did Insitro, Inc. do this quarter?”
“Is Insitro, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Insitro, Inc. do?+
Insitro is an AI therapeutics company built on causal biology that generates an integrated, multimodal corpus of human and cellular data and analyzes it with machine learning to reveal how disease begins, progresses, ...
What is Insitro, Inc.'s Cyborg Score?+
Insitro, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Insitro, Inc.'s main competitors?+
Named competitors include Exscientia, Recursion Pharmaceuticals, Verge Genomics, Numerion Labs. The full competitive landscape is in the AskCyborg report.
How can I get the full Insitro, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Insitro, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Insitro, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.